Amneal Pharmaceuticals, Inc.
NYSE:AMRX
7.45 (USD) • At close June 3, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,793.957 | 2,393.607 | 2,212.304 | 2,093.669 | 1,992.523 | 1,626.373 | 1,662.991 | 1,033.654 | 1,018.225 | 866.28 | 785.623 |
| Cost of Revenue
| 1,773.519 | 1,529.738 | 1,427.596 | 1,309.72 | 1,364.13 | 1,273.376 | 946.588 | 507.476 | 420.77 | 367.054 | 335.989 |
| Gross Profit
| 1,020.438 | 820.565 | 791.461 | 783.949 | 628.393 | 352.997 | 716.403 | 526.178 | 597.455 | 499.226 | 449.634 |
| Gross Profit Ratio
| 0.365 | 0.343 | 0.358 | 0.374 | 0.315 | 0.217 | 0.431 | 0.509 | 0.587 | 0.576 | 0.572 |
| Reseach & Development Expenses
| 196.559 | 194.75 | 200.046 | 209.563 | 190.585 | 202.287 | 210.451 | 191.938 | 204.747 | 136.87 | 106.735 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 230.435 | 109.046 | 118.757 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 476.436 | 429.675 | 399.7 | 365.504 | 326.727 | 289.598 | 230.435 | 109.046 | 118.757 | 109.679 | 84.615 |
| Other Expenses
| 98.117 | 18.738 | -3.96 | 41.19 | 19.926 | 1.465 | 2.848 | -0.047 | -0.669 | 0 | 0 |
| Operating Expenses
| 667.15 | 659.495 | 595.786 | 616.257 | 537.238 | 491.885 | 440.886 | 300.984 | 323.504 | 277.809 | 239.639 |
| Operating Income
| 249.326 | 204.374 | -94.928 | 152.716 | 91.155 | -137.423 | -19.673 | 245.103 | 284.881 | 227.23 | 222.942 |
| Operating Income Ratio
| 0.089 | 0.085 | -0.043 | 0.073 | 0.046 | -0.084 | -0.012 | 0.237 | 0.28 | 0.262 | 0.284 |
| Total Other Income Expenses Net
| -304.339 | -244.644 | -153.199 | -121.35 | -126.935 | 28.44 | -183.049 | -73.78 | -70.06 | -60.576 | -39.244 |
| Income Before Tax
| -55.013 | -40.27 | -248.127 | 31.366 | -35.78 | -220.242 | -202.722 | 171.323 | 214.821 | 175.582 | 179.331 |
| Income Before Tax Ratio
| -0.02 | -0.017 | -0.112 | 0.015 | -0.018 | -0.135 | -0.122 | 0.166 | 0.211 | 0.203 | 0.228 |
| Income Tax Expense
| 18.863 | 8.452 | 6.662 | 11.196 | -104.358 | 383.331 | -1.419 | 1.998 | 5.395 | 4.951 | 1.513 |
| Net Income
| -116.886 | -83.993 | -129.986 | 10.624 | 91.059 | -603.573 | -169.726 | 167.648 | 207.378 | 169.451 | 176.928 |
| Net Income Ratio
| -0.042 | -0.035 | -0.059 | 0.005 | 0.046 | -0.371 | -0.102 | 0.162 | 0.204 | 0.196 | 0.225 |
| EPS
| -0.38 | -0.48 | -0.86 | 0.07 | 0.62 | -4.57 | -1.33 | 1.46 | 1.81 | 0.9 | 0.94 |
| EPS Diluted
| -0.38 | -0.48 | -0.86 | 0.07 | 0.61 | -4.57 | -1.33 | 1.46 | 1.81 | 0.9 | 0.94 |
| EBITDA
| 439.773 | 399.759 | 150.425 | 401.097 | 345.605 | 155.198 | -19.673 | 271.13 | 306.967 | 252.677 | 243.284 |
| EBITDA Ratio
| 0.157 | 0.167 | 0.068 | 0.192 | 0.173 | 0.095 | -0.012 | 0.262 | 0.301 | 0.292 | 0.31 |